Cots, food, water and other essential items will be available but resources are limited.

Ferreri serves as a Literacy Coach and Interventionist, while also advising HMS TOPS — Together Our Peers Succeed.

Alpha Tau Medical targets major 2026 catalysts as Alpha DaRT gains momentum; key pancreatic & GBM readouts ahead. Read the full analysis here of DRTS stock.

JERUSALEM, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® ...

An update from Alpha Tau Medical Ltd ( (DRTS)) is now available. On January 6, 2026, Alpha Tau Medical reported final results from its first-in-human pancreatic ductal adenocarcinoma study in Montreal ...

JERUSALEM, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® today announced the ...

Investing.com - Alpha Tau Medical Ltd. (NASDAQ:DRTS) has submitted the first module of a pre-market approval (PMA) application to the FDA for its Alpha DaRT treatment for recurrent cutaneous squamous ...

- Initial module submission marks an important milestone in the pre-market approval process - - Flexible modular submission framework granted to Alpha Tau by the FDA allows for streamlined review and ...

- Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first two patients - - Immune markers demonstrate immune system preservation ...

Investing.com - H.C. Wainwright has reiterated a Buy rating on Alpha Tau Medical Ltd. (NASDAQ:DRTS) with a price target of $9.00 following the company’s presentation of final results from its first-in ...